Successful treatment with denosumab for pelvic fibrous dysplasia
A case report and review of the literature
Kunihiro Ikuta, MD, PhD,a,∗ Tomohisa Sakai, MD, PhD,a Hiroshi Koike, MD, PhD,a Kan Ito, MD, PhD,a, Shiro Imagama, MD, PhD,a, Yoshihiro Nishida, MD, PhD,a,b

Abstract
Rationale: Fibrous dysplasia is a rare disorder that results in fractures, pain, and disability and can affect any bone in the body. The treatment of symptomatic fibrous dysplasia is determined based on the affected bones. Although some lesions are often too extensive for surgical procedures, there are currently no effective or recommended medical treatments available for them.

Patient concerns: A 27-year-old woman developed right buttock pain and was diagnosed with a bone tumor in the right ilium. Clinical images revealed an expansive osteolytic lesion with thinning of the cortex and cystic change from the acetabulum to the sacroiliac joint.

Diagnosis: An incisional biopsy was performed, and the lesion was diagnosed as cystic fibrous dysplasia. Occasional osteoclast-like giant cells and woven bone were observed. The patient had no evidence of polyostotic lesions or findings of McCune-Albright syndrome. Biochemical blood test results showed no obvious abnormal values, except for an increase in serum tartrate-resistant acid phosphatase 5b to 459 mU/dL.

Interventions: Since surgical treatment appeared to be challenging, she was treated with denosumab with decreased dose-intensity schedules.

Outcomes: The administration of denosumab caused osteosclerosis within the lesion, resulting in the elimination of bone pain. The patient received denosumab treatment for 18 months. Pain relief and lesion radiodensity were maintained for 9 months after denosumab discontinuation. The serum level of tartrate-resistant acid phosphatase 5b was measured to monitor the response to denosumab, which was suppressed during denosumab treatment.

Lessons: We described successful denosumab treatment in a patient with cystic fibrous dysplasia (FD) who maintained efficacy for 9 months after treatment. Although the use of denosumab in fibrous dysplasia is currently off-label, our experience with this patient supports the potential of denosumab therapy for patients for whom surgical treatment is challenging.

Abbreviations: CT = computed tomography, FD = fibrous dysplasia, GCTB = giant cell tumor of bone, MAS = McCune-Albright syndrome, NRS = numerical rating scale, TRACP-5b = tartrate-resistant acid phosphatase 5b.

Keywords: cystic fibrous dysplasia, denosumab, pelvis, tartrate-resistant acid phosphatase 5b
1. Introduction

Fibrous dysplasia (FD) is a skeletal disorder characterized by the replacement of the trabecular bone with abnormal fibrous and immature osseous tissue. FD can be either monostotic or polyostotic and affects any bone in the body, most commonly the femur, tibia, ribs, skull, humerus, and pelvis. The polyostotic type is often associated with McCune-Albright syndrome (MAS), which has café-au-lait macules and endocrinopathies or precocious puberty. FD involves a somatic mutation in GNAS, a gene encoding the Gsα protein, a guanine nucleotide-binding protein (G protein) that mediates intracellular signaling.[1,2]

Although most patients with FD experience few or no symptoms, surgical procedures are required for some patients with persistent pain, risk of pathological fracture, bone deformity, or prolonged fracture healing. These patients may undergo curettage and bone grafting, but the grafted bone tends to be resorbed in younger patients or those with the polyostotic type. Pain is more likely to occur if the lesion is located in a weight-bearing bone with thinning of the cortex. Significantly, the surgical treatment of pelvic lesions is challenging due to their anatomical complexity, difficulty in controlling hemorrhage, and risk of damage to the acetabulum or sacroiliac joint, which can impair pelvic or hip function. Therefore, alternative treatments are required for patients with symptomatic pelvic lesions.

Previous studies have implicated increased osteoclast activity in the pathophysiology of FD.[3,4] Several reports have proposed that antiresorptive treatments, mainly intravenous bisphosphonates, would be helpful for decreasing bone pain in symptomatic FD.[1,5] However, there is no evidence that bisphosphonates directly affect FD lesions by reducing their growth or disease activity.[1-5] There are no guidelines for the optimal treatment of symptomatic FD when the lesion is unsuitable for surgical treatment.

Denosumab is a humanized monoclonal antibody that binds to the cytokine receptor activator of nuclear factor-kappa B ligand and prevents it from activating the RANK receptor of osteoclasts, thereby inhibiting osteoclast function. Previous in vitro studies have shown that Gsα mutations upregulate Receptor activator of nuclear factor-kappa B ligand expression in FD.[6] Thus, denosumab may be useful in the treatment of FD and deserves further investigation. Treatment with denosumab has been reported to demonstrate a successful response in a small number of patients with FD.[7-12] Here, we report a case of a young woman with monostotic FD in the right ilium that was treated with periodic administration of denosumab.

2. Case presentation

A 27-year-old woman was referred to our department with radiographs taken at a local clinic for persistent pain in her right hip after a skiing fall. At the time of her first visit, she was limping, and the range of motion of her right hip was limited. Plain radiography revealed a large osteolytic lesion in the right ilium (Fig. 1A). Computed tomography (CT) revealed an expanding lesion with thinning of the cortex from the acetabulum to the sacroiliac joint (Fig. 1b and 1c). Magnetic resonance imaging revealed no extra-skeletal masses. The lesion included areas showing an iso-signal intensity compared with that of skeletal muscle on T1-weighted images, a higher signal intensity on T2-weighted images, and an enhanced margin of the lesion with gadolinium, suggesting the presence of cystic degeneration.

![Figure 1. Images at initial visit (A) Plain radiograph showing a large osteolytic lesion (arrows) on the right ilium. (B) Axial view of pelvic computed tomography (CT) showing an expansile lytic lesion with cortical thinning. (C) Coronal CT showing the lesion extending to the subchondral bone of the acetabulum. (D) Axial T2-weighted magnetic resonance (MR) imaging revealed a multilocular lesion with high signal intensity, and (E) T1-fat suppressed axial MR image showing the lesion to be heterogeneously enhanced with gadolinium. (F) Bone scintigraphy showing increased focal uptake in the right ilium.](image-url)
(Fig. 1d and 1e). Clinical images were suggestive of bone tumors such as giant cell tumor of bone (GCTB), aneurysmal bone cyst, and FD. Histological examination following incisional biopsy showed irregular trabeculae with fibrous stroma (Fig. 2A) mixed with fibrous membrane tissues. Features of atypia were not found, while osteoclast-like giant cells were occasionally observed. (Fig. 2B). Based on these findings, a diagnosis of FD with cystic changes was made. Bone scintigraphy confirmed the presence of increased uptake in the right ilium (Fig. 1F). The patient had no evidence of polyostotic lesions or MAS symptoms. Her biochemical blood test results showed no obvious abnormal values, except for an increase in serum tartrate-resistant acid phosphatase 5b (TRACP-5b) to 459 mU/dL.

She could not work due to right hip pain, expressed as 8/10 on a numerical rating scale (NRS) at that time. Considering the invasiveness or the possibility of massive hemorrhage induced by surgical intervention, the lesion was not considered amenable to intralesional curettage and bone grafting. Considering the patient’s preference, we decided on conservative therapy, and denosumab was administered according to the established protocol in GCTB under off-label use approval at our institution. The patient provided informed consent for the treatment with denosumab. Regular dental evaluations were also conducted.

Denosumab was administered at 120 mg/day on days 1, 8, 15, and 29, and monthly thereafter, in addition to daily calcium supplementation. After 4 weeks (day 29) of denosumab administration, the hip pain showed a marked decline (NRS 2/10), and she was able to return to work. Since hypocalcemia (7.9 mg/dL) was observed as a side effect of denosumab administration, vitamin D supplementation was started. CT images after 3 months of denosumab therapy revealed increased osteosclerotic areas within the osteolytic lesion (Fig. 3a and 3b). No reduction in the size of the affected areas was observed. After 3 months of treatment, denosumab administration was decreased to once every 2 months. Six months after denosumab treatment, the osteosclerotic changes in the lesion became more prominent (Fig. 3C), and the hip pain completely disappeared (NRS 0/10) (Fig. 3F). The serum TRACP-5b level decreased to below the lower limit of normal (49 mU/dL) after 6 months of denosumab treatment. Since the symptoms and disease status were stable, denosumab administration was decreased to once every 3 months from 12 months after the treatment (Fig. 3D). At 18 months of treatment, denosumab was discontinued because the patient wanted to become pregnant. The TRACP-5b level at that time was 40 mU/dL.

Biochemical blood tests were performed routinely after discontinuation of denosumab treatment, but hypercalcemia was not observed. CT revealed increased osteolytic changes within the lesion, and the hip pain flared up nine months after discontinuation of treatment (Fig. 3E). The TRACP-5b level remained within the normal range but increased to 251 mU/dL. The patient did not resume denosumab treatment because of her desire to have a baby. At the last visit, 15 months after denosumab discontinuation, she was able to work with mild hip pain (NRS 3/10) controlled without analgesics. The serum TRACP-5b level further increased to 318 mU/dL but was still below the upper limit of the normal range (Fig. 3F).

3. Discussion

Although polyostotic FD is commonly associated with flat bones, monostotic FD in the pelvis is rare. The typical radiographic finding of FD is a hazy, “ground glass-like” appearance. However, the presence of hemorrhage, secondary aneurysmal bone cyst formation, mucinous degeneration, and cystic changes can lead to diagnostic confusion. In our case, the radiographic features of the lesion depicted osteolysis and expansion with cystic changes and cortical thinning, which led us to consider the possibility of giant cell tumor of bone. Pathological examination revealed cystic FD. Cystic FD is not uncommon in the skull, facial bones, and ribs, and it has been sporadically reported in long tubular bones. Longstanding FD lesions can be accompanied by cystic changes. However, there have been no reports on how often FD lesions in the pelvis are associated with cystic changes.

In this case, the dosing intervals for denosumab were altered depending on the disease activity. Data on long-term denosumab administration were not obtained due to the patient’s desire to have a baby, but efficacy may be observed even at longer dosing intervals. Several recent reports have shown that patients with refractory FD benefit from denosumab treatment with different schedules and doses (Table 1). Majoor et al suggested...
that a treatment regimen of 60 mg every 6 months was insufficient to achieve a sustained reduction of bone turnover markers in patients with FD, and all patients were eventually treated with 60 mg of denosumab every 3 months. Favorable clinical responses to treatment with denosumab in these reports and our case support further investigation regarding the potential use of denosumab in patients with refractory FD. On the other hand, it was recommended that denosumab be used in specialized facilities, preferably within the framework of clinical studies or trials in the guidelines from the International FD/MAS International Consortium. A clinical trial in FD is currently underway to evaluate the clinical efficacy and histological effects of denosumab treatment, including the biochemical response after discontinuation (NCT03571191). In the trial, the dosage and dosing intervals followed the protocol of GCTB administered to our patient in the first 3 months of treatment.

In patients with unresectable or metastatic GCTB, control of the disease by prolonged administration is attempted in a clinical setting. However, even in GCTB, for which denosumab has been approved, there is still a lack of evidence regarding the optimal duration of treatment, appropriate dosing intervals, and risks of long-term administration for patients requiring long-term disease...
### Table 1

Cases with FD treated with denosumab in the previous literature.

| References          | Number of patients | FD type | Treatment | Effect on bone pain | Bone resorption marker | Radiographic improvement | BPs prior to denosumab treatment | Adverse events                                      | Duration of denosumab treatment |
|---------------------|--------------------|---------|-----------|--------------------|------------------------|--------------------------|----------------------------------|-----------------------------------|----------------------------------|
| Boyce, 2012[12]    | 1                  | MAS     | 1 mg/kg, every 3 M | Yes                | CTX                   | No                       | Yes                             | Hypercalcemia after discontinuation | 7 M                             |
| Ganda, 2013[10]     | 2                  | PFD (2) | 60 mg, every 6–9 M (case 1), every 4 M (case 2) | Yes               | uDPD                  | NA                       | Yes                             | None                              | NA                               |
| Eller-Vainicher, 2016[7] | 1              | MFD     | 60 mg, every 3 M    | Yes                | CTX                   | Yes                      | Yes                             | None                              | 5 M                             |
| Majoor, 2019[9]     | 12                 | PFD (7) | MAS (4) MFD (1)     | No                 | CTX                   | NA                       | Yes                             | Skin rash(1), Osteonecrosis of jaw(1), oral blisters (1) | 27 M median 15.5 M, median 1.6 yr |
| Meier, 2021[8]      | 37                 | PFD (21) | 60 mg, every 3–6 M  | Yes (10)            | CTX                   | NA                       | No                              | NA                                | NA                               |
| van der Bruggen, 2021[11] | 8              | PFD (5) | MAS (2) MFD (1)     | NA                 | NA                    | Yes                      | Yes                             | Hypercalcemia after discontinuation | NA                               |
| Raborn, 2021[11]    | 1                  | MFD     | 60–120 mg, every 3–6 M | Yes                | CTX                   | Yes                      | Yes                             | None                              | 3.5 yr                           |
| Meier, 2021[8]      | 2                  | PFD (2) | 60 mg, every 3M     | Yes                | CTX                   | Yes                      | No                              | NA                                | 5.3–5.5 yr                      |

**Notes:**
- BPs = bisphosphonates, CTX = C-terminal telopeptide of type I collagen, FD = fibrous dysplasia, M = months, MAS = McCune-Albright syndrome, MFD = monostotic fibrous dysplasia, NA = not available, PFD = polyostotic fibrous dysplasia, uDPD = urinary deoxypyridinoline.
- The figures in parentheses indicate the number of patients.
- Effect of bone pain was evaluated as a mean score.

---

**Author contributions**

- **Writing – original draft:** Kunihiro Ikuta, Tomohisa Sakai
- **Writing – review & editing:** Shiro Imagama, Yoshihiro Nishida
- **Visualization:** Yoshihiro Nishida
- **Conceptualization:** Kunihiro Ikuta, Tomohisa Sakai, Yoshihiro Nishida
- **Supervision:** Shiro Imagama
- **Data curation:** Kan Ito, Shiro Imagama, Yoshihiro Nishida
- **Funding acquisition:** Kunihiro Ikuta
- **Methodology:** Yoshihiro Nishida
- **Writing:** Kunihiro Ikuta

---

**Acknowledgment**

The authors thank Satoko Shimada, a pathologist of Nagoya University Hospital, for the pathological diagnosis of the disease.
References

[1] Javaid MK, Boyce A, Appelman-Dijkstra N, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis 2019;14:1-17.

[2] Weinstein LS. Gsα mutations in fibrous dysplasia and McCune-Albright syndrome. J Bone Miner Res 2007;22:120-4.

[3] Yamamoto T, Ozono K, Kasayama S, et al. Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 1996;98:30-5.

[4] Riminucci M, Kuznetsov SA, Cherman N, Corsi A, Bianco P, Gehron Robey P. Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Bone 2003;33:434-42.

[5] Chapurlat R, Legrand MA. Bisphosphonates for the treatment of fibrous dysplasia of bone. Bone 2021;143:115784. doi: 10.1016/j.bone.2020.115784.

[6] Piersanti S, Remoli C, Saggio I, et al. Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors. J Bone Miner Res 2010;25:1103-16.

[7] Eller-Vainicher C, Rossi DS, Guglielmi G, et al. Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia. Clin Cases Miner Bone Metab 2016;13:253-6.

[8] Meier ME, van der Bruggen W, van de Sande MAJ, Appelman-Dijkstra NM. Regression of fibrous dysplasia in response to denosumab therapy: a report of two cases. Bone Reports 2021;14:101058. doi: 10.1016/j.bonr.2021.101058.

[9] Majoor BCJ, Papapoulos SE, Sander Dijkstra PD, Fiocco M, Hamdy NAT, Appelman-Dijkstra NM. Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates. J Clin Endocrinol Metab 2019;104:6069-78.

[10] Ganda K, Seibel MJ. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases. Osteoporos Int 2014;25:777-82.

[11] Raborn LN, Burke AB, Ebb DH, Collins MT, Kaban LB, Boyce AM. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects. Osteoporos Int 2021;32:1889-93.

[12] Boyce AM, Chong WH, Yao J, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res 2012;27:1462-70.

[13] Howard D, Dorfman BC. Bone Tumor. 1st edition. Missouri: Mosby Inc; 1998.

[14] Kinnunen AR, Sironen R, Sipola P. Magnetic resonance imaging characteristics in patients with histopathologically proven fibrous dysplasia—a systematic review. Skeletal Radiol 2020;49:837-45.

[15] Okada K, Yoshida S, Okane K, Sageshima M. Cystic fibrous dysplasia mimicking giant cell tumor: MRI appearance. Skeletal Radiol 2000;29:45-8.

[16] Siegal GP, Bloem JL, Cates JM. WHO Classification of Tumors of Soft Tissue and Bone. 5th ed.Lyon: IARC Press; 2020.

[17] Meier ME, Clerkx SN, Winter EM, et al. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. J Bone Miner Res 2021;36:1729-38.

[18] Meier ME, van der Bruggen W, Vriens D, Meier ME, et al. Denosumab reduces lesional fluorine skeletal burden on Na[18F]F PET-CT in patients with fibrous dysplasia/McCune-albright syndrome. J Clin Endocrinol Metab 2021;106:e2980-94.

[19] Palmerini E, Chawla NS, Ferrari S, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer 2017;76:118-24.